Objectives: Recently, matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was successfully applied for the detection of carbapenemase activity directly from Gram-negative colonies. Based on this principle, we evaluated the performance of MALDI-TOF MS for rapid detection of carbapenemase activity directly from positive blood culture vials.
Introduction
Recently, matrix-assisted laser desorption ionization -time-offlight mass spectrometry (MALDI-TOF MS) has emerged as an important tool in clinical microbiology laboratories. This methodology is fast, simple, accurate and cost-effective to routinely identify bacterial isolates. 1 In addition, it has been also applied for rapid identification of pathogens directly from positive blood culture vials. 2, 3 However, the time required for reporting antimicrobial susceptibility results is still of crucial importance for readjustment of antimicrobial therapy. Although MALDI-TOF MS has been integrated into automated antimicrobial susceptibility testing platforms, these systems habitually do not accurately report the carbapenem MICs for carbapenemase-producing Enterobacteriaceae. 4 -9 Thus, the accurate detection of carbapenemase production is still necessary.
MALDI-TOF MS has detected activity of different carbapenemases directly from bacterial colonies with great specificity and sensitivity. 10 -12 It has the potential to detect carbapenemase activity independent of the enzyme produced, including novel enzymes. Based on these facts, we focused on evaluating the performance of MALDI-TOF MS for the first time to rapidly detect carbapenemase activity directly from blood culture vials.
Methods

Standardization of bacterial pellet for carbapenemase detection
Initially, three carbapenemase-producing strains (KPC-2-producing Klebsiella pneumoniae ATCC BAA 1705, SPM-1-producing Pseudomonas aeruginosa 48-1997A and OXA-23-producing Acinetobacter baumannii 2387-08A) and a negative control strain (K. pneumoniae ATCC BAA 1706) were inoculated into four BD Bactec TM Plus Aerobic blood culture bottles (Becton Dickinson, USA) with an inoculum corresponding to 1000 cfu for each strain. 13, 14 The vials were then introduced into a Bactec 9240 TM blood culture system. 
Bacterial extraction for MALDI-TOF MS experiments
The investigators were blinded to Gram stain results during MALDI-TOF MS experiments. The positive blood culture vials were submitted to bacterial extraction, MALDI-TOF MS carbapenemase assay and bacterial identification. An aliquot of 8 mL was retrieved from each positive blood culture vial on the same day that the bacterial growth was flagged on the Bactec 9240 TM blood culture system and placed into a sterile tube containing a separator gel and clot activator (BD Vacutainer SST II Advance TM , Becton Dickinson, USA). The tubes were centrifuged at 10 000 rpm for 10 min. The bacterial pellet was visible at the outer surface of the separator gel. The supernatant was removed and the bacterial pellet was washed with 1 mL of sterile water to obtain the bacterial inoculum. This mixture was transferred to a 1.5 mL sterile tube. The clear bacterial pellet was tested for carbapenemase assay following whole bacterial protein extraction for the identification procedure as previously described.
2,10
Detection of carbapenemase activity by MALDI-TOF MS
A fresh ertapenem solution (0.5 g/L) was prepared using Tris-HCl 20 mM pH adjusted, as previous reported. 10 A 500 mL aliquot of ertapenem solution was added to the bacterial pellet tube, gently mixed and incubated at 378C for 2 and 4 h. The tubes were then centrifuged at 13 000 rpm for 2 min and 1 mL of the supernatant was spotted onto a stainless steel MALDI target plate (Bruker Daltonics, Bremen, Germany). One microlitre of a-cyano-4-hydroxycinnamic acid matrix solution (Bruker Daltonics, Bremen, Germany) was placed on each spot and allowed to dry at room temperature. A mass spectrum was obtained using a Bruker Daltonics Microflex LT instrument (Bruker Daltonics, Bremen, Germany) operating in accordance with the manufacturer's instructions as recommended. 10 Carbapenem hydrolysis was considered positive if the corresponding ertapenem intact molecule mass peak (475 m/z and its monosodium salt, 497 m/z) completely disappeared. 10 In each assay, a fresh inoculum of K. pneumoniae ATCC BAA 1705 and of K. pneumoniae ATCC BAA 1706 were tested as the positive and negative controls, respectively, as well as a tube containing only the ertapenem solution. The detection of carbapenemase activity by MALDI-TOF MS was also performed directly from the colonies of all Gram-negative isolates to confirm the initial results.
Molecular characterization of carbapenemases
PCRs targeting genes encoding KPC-like, NDM-1, OXA-48, metallo-blactamases and carbapenem-hydrolysing class D b-lactamases (CHDLs) were performed using primers previously described followed by DNA sequencing of the respective amplicons. 13,16 -19 Results During the study period, 100 blood culture vials were flagged as positive and were further evaluated. Among them, the presence of two different pathogens was detected in 10 positive blood culture vials resulting in a total of 110 bacterial isolates. K. pneumoniae (27; 24.5%) was the most frequent pathogen isolated, followed by coagulase-negative Staphylococcus (19; 17.3%) and Escherichia coli (18; 16.4%). Overall, MALDI-TOF MS correctly identified 81.8% (90/110) of bacterial isolates tested directly from blood culture vials and 97.2% (107/110) after colony isolation. All positive blood culture vials were submitted to carbapenemase assay, including those where Gram-positive bacteria were subsequently isolated. The MALDI-TOF MS carbapenemase assay detected 21 isolates as carbapenemase producers directly from blood culture vials at the time of positivity (day 1). Among those, 17 isolates (13 K. pneumoniae, 2 Enterobacter cloacae, 1 P. aeruginosa and 1 A. baumannii) were detected within a 2 h incubation period, while the remaining 4 isolates (2 K. pneumoniae and 2 A. baumannii) required an extended incubation period (Table 1 and Figure 1 ). Among the 11 carbapenemase-producing A. baumannii isolates, only 3 isolates were directly detected from blood culture vials on day 1. The eight remaining isolates were successfully identified as carbapenemase producers only by testing bacterial colonies on the next day (day 2), making a total of 29 carbapenemase-producing Gram-negative isolates detected by MALDI-TOF MS. As expected, all Gram-positive isolates yielded negative results. Molecular characterization of carbapenemase Carbapenemase detection in blood cultures by MALDI-TOF MS genes was performed among the Gram-negative isolates (76/110; 69.1%). Among these, all 29 isolates (38.2%) detected by MALDI-TOF MS as carbapenemase producers were confirmed to carry carbapenemase-encoding genes by PCR and DNA sequencing ( Table 1 ). The bla KPC-2 gene was detected in 17 Enterobacteriaceae isolates (15 K. pneumoniae and 2 E. cloacae), followed by CHDL-encoding genes in 11 A. baumannii isolates (bla OXA-23 , n¼10; bla OXA-72 , n¼1) and the bla SPM-1 gene in 1 P. aeruginosa isolate ( Table 1 ). The carbapenem MICs for carbapenemaseproducing isolates are described in Table 1 . All CHDL-producing A. baumannii and SPM-1-producing P. aeruginosa isolates were not susceptible to imipenem and meropenem by agar dilution and Phoenix. Moreover, all KPC-producing Enterobacteriaceae were not susceptible to ertapenem by either methodology. In contrast, 7 of 17 KPC-producing isolates were susceptible to imipenem and meropenem by the Phoenix system (MIC ≤1 mg/L). According to CLSI agar dilution, only a single isolate was confirmed to be resistant to meropenem (MIC 64 mg/L) while six isolates were not susceptible to imipenem (MICs 2-32 mg/L).
Discussion
Currently, according to CLSI and EUCAST guidelines, clinical laboratories should report the category of susceptibility to carbapenems without confirming the production of carbapenemases, since Gram-negative bacteria may possess other mechanisms of carbapenem resistance. However, automated systems habitually fail to determine carbapenem MICs for carbapenemase-producing Enterobacteriaceae. Consequently, based only on antimicrobial susceptibility results, carbapenem prescription may be disregarded, leading to the use of more toxic compounds. Recently, EUCAST developed a new guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Phenotypic double-disc synergy tests have been recommended by EUCAST to detect carbapenemase activity among Enterobacteriaceae isolates. However, these tests require an overnight incubation period and molecular confirmation of the results is usually necessary. Molecular-based methods, although more rapid and accurate, are unable to detect new carbapenemase-encoding genes, require a high degree of expertise and are still expensive for routine use in some geographic regions. In addition, the detection of a carbapenemase-encoding gene by PCR does not guarantee its expression. 20 MALDI-TOF MS is the latest advance to detect carbapenemase activity. Recently, it was successfully employed to identify carbapenem hydrolysis products directly from Gram-negative bacterial colonies. 10 -12 In our study, we report for the first time that MALDI-TOF MS was able to detect carbapenemase activity directly from positive blood culture vials for all KPC-2-producing and SPM-1-producing isolates. This is in accordance with previous studies that demonstrated the high sensitivity (100%) and specificity (100%) of MALDI-TOF MS for detecting the carbapenemase activity of KPC-2-, KPC-3-or SPM-1-producing isolates from bacterial colonies. 10 -12 In contrast, the detection of CHDL activity was not so easily achieved with this methodology. Carbapenem resistance in Acinetobacter spp. is mainly mediated by the production of CHDLs. 21, 22 In our study, all but one CHDL detected was OXA-23, which is the most disseminated CHDL in A. baumannii worldwide. 23 The majority of CHDLs weakly hydrolyse carbapenems, which may compromise their detection by susceptibility testing and other phenotypic tests. Therefore, PCR-based methods remain the 'gold standard' for the identification of CHDLs. 22 In our study, the MALDI-TOF MS methodology was able to identify the carbapenemase activity of all CHDL-producing Acinetobacter spp. isolates only when bacterial colonies were tested and the assay was incubated for an extended period (4 h) as previously observed. 10 Therefore, MALDI-TOF MS may constitute an alternative to PCR-based methods for the detection of CHDLs, but only after isolation of bacterial colonies.
Conclusions
MALDI-TOF MS has been revolutionizing bacterial identification in clinical laboratories, especially due to its simplicity and rapid turnaround time. Similarly, the detection of carbapenemase activity by MALDI-TOF MS directly from clinical blood culture vials may provide a quick answer for faster readjustment of antimicrobial therapy and implementation of infection control measures. In summary, MALDI-TOF MS empowers clinical laboratories to address a clinical demand for faster results.
